Anil Abraham Joy, BSc (Pharmacology), MD, FRCPC (Internal Medicine, Medical Oncology)

Professor, Faculty of Medicine & Dentistry - Oncology Dept

Personal Website: https://pubmed.ncbi.nlm.nih.gov/?term=joy+aa

Contact

Professor, Faculty of Medicine & Dentistry - Oncology Dept
Email
Phone
(780) 432-8556

Overview

Area of Study / Keywords

Breast Cancer Lung Cancer Thoracic Cancer Clinical Trials Research Phase II/III Advocacy Global


About

Dr. Anil Abraham Joy is a Professor in the Department of Oncology, Division of Medical Oncology in the Faculty of Medicine and Dentistry at the University of Alberta and has been a Staff Medical Oncologist at the Cross Cancer Institute since 2003.

His past appointments include being Chair for the Northern Alberta Breast Cancer Program, Provincial Chair for the Alberta Breast Cancer Program and has also served as a member of the Canadian Agency for Drugs and Technologies in Health (CADTH)[now known as Canadian Drug Agency] pan-Canadian Oncology Drug Review (pCODR) – on the Expert Review Committee (pERC). He is the current Research Lead for the Breast Cancer Program at the Cross Cancer Institute

Dr. Joy's primary clinical and translational research areas include breast and thoracic malignancies. He has ongoing interest in therapeutic pharmaceuticals and lifestyle interventional research, guideline/consensus development, global oncology/regional disparity issues, medical education, as well as promoting a culture of wellness.

He has multiple research grants/funding (investigator initiated and industry) in collaboration with other basic science, clinical and translational researchers and has multiple publications to date (>140) [see: https://pubmed.ncbi.nlm.nih.gov/?term=joy+aa]. 

He is a keen advocate and collaborator for cancer prevention, diagnosis, treatment and survivorship.


Research

https://pubmed.ncbi.nlm.nih.gov/?term=joy+aa

Announcements

Not currently accepting research students 

(Information updated as of February 28, 2025)

Featured Publications

Tandon P., Purdy G., Ismond K.P., Cruz C., Etruw E., Suderman K., Hyde A., Stickland M., Spence J.C., Lien D.C., Bhanji R., Prado C.M., Cruz A.M., Joy A.A., Yaskina M., Round J., Harback K., Padwal R., McNeely M.L.

Contemporary Clinical Trials. 2022 May; 118 10.1016/j.cct.2022.106791


Kirkham A.A., Ford K.L., Topolnyski J., Da Silva B.R., Paterson D.I., Prado C.M., Joy A.A., Boulé N.G., Pituskin E., Haykowsky M.J., Thompson R.B.

JACC: CardioOncology. 2022 May; 4 (2):276-278 10.1016/j.jaccao.2022.03.002


McNeely M.L., Suderman K., Yurick J.L., Nishimura K., Sellar C., Ospina P.A., Pituskin E., Lau H., Easaw J.C., Parliament M.B., Joy A.A., Culos-Reed S.N.

Cancers. 2022 May; 14 (11) 10.3390/cancers14112737


Ferrario C., Christofides A., Joy A.A., Laing K., Gelmon K., Brezden-Masley C.

Current Oncology. 2022 April; 29 (4):2720-2734 10.3390/curroncol29040222


Oberoi D., Kwok C., Li Y., Railton C., Horsman S., Reynolds K., Joy A.A., King K.M., Lupichuk S.M., Speca M., Culos-Reed N., Carlson L.E., Giese-Davis J.

BMC Medical Research Methodology. 2022 March; 22 (1) 10.1186/s12874-022-01549-1


Gandhi S., Brackstone M., Hong N.J.L., Grenier D., Donovan E., Lu F.I., Skarpathiotakis M., Lee J., Boileau J.F., Perera F., Simmons C., Joy A.A., Tran W.T., Tyono I., Van Massop A., Khalfan S.

BREAST CANCER RESEARCH AND TREATMENT. 2022 February; 193 (1) 10.1007/s10549-022-06522-6


SERENA-4: Phase III Trial of AZD9833 + Palbociclib Versus Anastrozole + Palbo-Ciclib in ER+/HER2- Advanced Breast Cancer

Japanese Society of Medical Oncology - Annual Meeting. 2022 February;


Simmons C., Rayson D., Joy A.A., Henning J.W., Lemieux J., McArthur H., Card P.B., Dent R., Brezden-Masley C.

Therapeutic Advances in Medical Oncology. 2022 January; 14 10.1177/17588359211066677


Elevated plasma IL-8 predicts for reduced outcomes in CCTG MA.38, a phase 2 randomized trial of palbociclib in ER+/HER2- metastatic breast cancer patients

San Antonio Breast Cancer Symposium. 2021 December;


SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.

San Antonio Breast Cancer Symposium. 2021 December;


Clinical Nutrition ESPEN. 2021 December; 10.1016/j.clnesp.2021.09.658


Leighl N.B., Laurie S.A., Goss G.D., Hughes B.G.M., Stockler M., Tsao M.S., Hwang D.M., Joubert P., Kulkarni S., Blais N., Joy A.A., Mates M., Rana P., Yadav S.K., Underhill C., Lee C., Bradbury P.A., Hiltz A., Dancey J., Ding K., Vera-Badillo F.

Journal of Thoracic Oncology. 2021 November; 17 (3):434-445 10.1016/j.jtho.2021.10.023


Weekday 16:8 Time-Restricted Eating in Breast Cancer Survivors: Feasibility, Safety, and Effects on Cardiometabolic Health

American Heart Association. 2021 November;


Zhu Z., Wang W., Lin F., Jordan T., Li G., Silverman S., Qiu S., Joy A.A., Chen C., Hockley D.L., Zhang X., Zhou Q., Postovit L.M., Zhang X., Hou Y., Mackey J.R., Li B., Wong G.K.S.

Cell Reports Medicine. 2021 October; 2 (10) 10.1016/j.xcrm.2021.100404


A Novel Composite Biomarker Panel For Detection Of Early Stage Non-Small Cell Lung Cancer

CARO 2021, Journal of the European Society for Radiotherapy and Oncology. 2021 October;


Kirkham A.A., King K., Joy A.A., Pelletier A.B., Mackey J.R., Young K., Zhu X., Meza-Junco J., Basi S.K., Hiller J.P., Brkin T., Michalowski B., Pituskin E., Paterson D.I., Courneya K.S., Thompson R.B., Prado C.M.

BMC CANCER. 2021 October; 21 (1) 10.1186/s12885-021-08808-2


Miles D., Ciruelos E., Schneeweiss A., Puglisi F., Peretz-Yablonski T., Campone M., Bondarenko I., Nowecki Z., et al.

ANNALS OF ONCOLOGY. 2021 October; 32 (10):1245-1255 10.1016/j.annonc.2021.06.024


Gelmon K., Walshe J.M., Mahtani R., Joy A.A., Karuturi M., Neven P., Lu D.R., Kim S., Schnell P., Bananis E., Schwartzberg L.

BREAST. 2021 October; 59 10.1016/j.breast.2021.07.017


Effect Of Palbociclib (PAL) + Endocrine Therapy (ET) On Time To Chemotherapy (TTC) Across Subgroups Of Patients (Pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer (ABC): Post Hoc Analyses From PALOMA-2 (P2) And PALOMA-3 (P3).

ESMO Conference 2021. 2021 September;


Clemons M., Liu M., Stober C., Pond G., Jemaan Alzahrani M., Ong M., Ernst S., Booth C., Mates M., Abraham Joy A., Aseyev O., Blanchette P., Vandermeer L., Tu M., Thavorn K., Fergusson D.

Journal of Bone Oncology. 2021 September; 30 10.1016/j.jbo.2021.100388


Clemons M., Fergusson D., Joy A.A., Thavorn K., Meza-Junco J., Hiller J.P., Mackey J., Ng T., Zhu X., Ibrahim M.F.K., Sienkiewicz M., Saunders D., Vandermeer L., Pond G., Basulaiman B., Awan A., Pitre L., Nixon N.A., Hutton B., Hilton J.F.

Breast Journal. 2021 August; 58 10.1016/j.breast.2021.03.012


Pituskin E., Joy A.A., Fairchild A.

Seminars in Oncology Nursing. 2021 August; 37 (4) 10.1016/j.soncn.2021.151176


Tu M.M., Clemons M., Stober C., Jeong A., Vandermeer L., Mates M., Blanchette P., Joy A.A., Aseyev O., Pond G., Fergusson D., Ng T.L., Thavorn K.

Current Oncology. 2021 June; 28 (3):1847-1856 10.3390/curroncol28030171


journal of clinical oncology. 2021 May; 10.1200/JCO.2021.39.15_suppl.TPS1101


Bedard E.L.R., Abraham A.G., Joy A.A., Ghosh S., Wang X., Lim A., Shao D., Loebenberg R., Roa W.H.

Clinical and Investigative Medicine. 2021 March; 44 (1):E15-E24 10.25011/cim.v44i1.36016


Joy A.A., Vos L.J., Pituskin E., Cook S.F., Bies R.R., Vlahadamis A., King K., Basi S.K., Meza-Junco J., Mackey J.R., Stanislaus A., Damaraju V.L., Damaraju S., Sawyer M.B.

Clinical Breast Cancer. 2021 March; 10.1016/j.clbc.2021.03.001


SABCS 2020, AACR, CANCER RESEARCH. 2021 February; 10.1158/1538-7445.SABCS20-PS10-14


LeVasseur N., Cheng W., Mazzarello S., Clemons M., Vandermeer L., Jones L., Joy A.A., Barbeau P., Wolfe D., Ahmadzai N., Hersi M., Stober C., Shorr R., Hilton J., Hutton B.

PLoS One. 2021 February; 16 (2 February) 10.1371/journal.pone.0245794


Clemons M., Ong M., Stober C., Ernst S., Booth C., Canil C., Mates M., Robinson A., Blanchette P., Joy A.A., Hilton J., Aseyev O., Pond G., Jeong A., Hutton B., Mazzarello S., Vandermeer L., Kushnir I., Fergusson D.

EUROPEAN JOURNAL OF CANCER. 2021 January; 142 10.1016/j.ejca.2020.08.019


View additional publications